Virtual Library

Start Your Search

M. Keshgtarpur



Author of

  • +

    P3.01 - Poster Session/ Treatment of Advanced Diseases – NSCLC (ID 208)

    • Event: WCLC 2015
    • Type: Poster
    • Track: Treatment of Advanced Diseases - NSCLC
    • Presentations: 1
    • +

      P3.01-060 - Prognostic Value of Serum Proteomic Test and of Comorbidity Index in Diversified Population with Lung Cancer (ID 1597)

      09:30 - 09:30  |  Author(s): M. Keshgtarpur

      • Abstract
      • Slides

      Background:
      Proteomic (VeriStrat®) serum test has prognostic and predictive value in response to erlotinib; but the relation between comorbidity index and test performance and usefulness of this test in different races has not been adequately studied yet.

      Methods:
      Patients and Methods: We have reviewed electronic records of lung cancer patients from 09/2009 till 07/2014who had proteomic test performed to help with therapy choice. Extracted data was analyzed for survival using SAS software 9.4.

      Results:
      Among 49 qualified patients, 31 had VeriStrat® test done before and 18 after the first line treatment for metastatic disease. Nineteen cases with good VeriStrat® (VSG) test received erlotinib, and 12 received chemotherapy; 4 cases with VeriStrat® poor (VSP) results received erlotinib and 12 received chemotherapy. When stratified for test results “VSG vs. VSP” overall survival did not differ between white race and other races (HR=1.005; 95%CI=0.43-2.35; p=0.99). There was a trend of better survival for combined effect of VeriStrat® good test (VSG) and African American (AA) race. Patients with VSG test had better survival than patients with VSP test in each Charlson comorbidity index (CCI) stratum.

      Conclusion:
      Our study shows that there is no significant impact of race on prognostic and predictive values of VeriStrat® test. Prognostic value of this test is independent of comorbidities and older age.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.